Vironova BioAnalytics
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 4.3m | 7.3m | 6.2m | 9.6m | 10.8m | 12.2m | 12.2m |
% growth | 24 % | 70 % | (14 %) | 54 % | 13 % | 12 % | - |
EBITDA | (4.8m) | (4.2m) | (7.5m) | (7.0m) | (16.6m) | - | - |
% EBITDA margin | (112 %) | (58 %) | (119 %) | (73 %) | (154 %) | - | - |
Profit | (5.7m) | (6.0m) | (10.3m) | (10.8m) | (20.3m) | - | - |
% profit margin | (134 %) | (83 %) | (164 %) | (113 %) | (187 %) | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Grant | ||
€290k | Grant | ||
* | N/A | Acquisition | |
Total Funding | AUD493k |
Related Content
Recent News about Vironova BioAnalytics
EditVironova AB is a biotechnology company specializing in the analysis of nanoparticles using Transmission Electron Microscopy (TEM). The company offers a comprehensive suite of hardware, software, and services designed to provide detailed and accurate nanoparticle analysis. Vironova serves clients in the pharmaceutical and biotechnology industries, helping them to ensure the quality and efficacy of their nanoparticle-based products. Operating in the high-tech biotechnology market, Vironova's business model revolves around selling specialized TEM equipment, proprietary software, and offering expert analytical services. The company generates revenue through the sale of its products, as well as through service contracts and consulting fees.
Keywords: TEM, nanoparticles, biotechnology, pharmaceutical, software, hardware, analysis, quality control, consulting, high-tech.